tiprankstipranks
Trending News
More News >
SelectQuote (SLQT)
NYSE:SLQT
Advertisement

SelectQuote (SLQT) AI Stock Analysis

Compare
401 Followers

Top Page

SLQT

SelectQuote

(NYSE:SLQT)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 4o)
Rating:49Neutral
Price Target:
$1.50
▼(-13.29% Downside)
SelectQuote's overall stock score is primarily impacted by its financial performance and technical analysis. While there are signs of recovery in revenue and gross profit margins, the company faces significant profitability and cash flow challenges. The bearish technical indicators and negative valuation metrics further contribute to a cautious outlook.

SelectQuote (SLQT) vs. SPDR S&P 500 ETF (SPY)

SelectQuote Business Overview & Revenue Model

Company DescriptionSelectQuote, Inc. operates a technology-enabled, direct-to-consumer distribution platform that sells a range of insurance policies to consumers from various insurance carriers in the United States. The company operates through three segments: Senior; Life; and Auto & Home. It distributes senior health policies, such as medicare advantage, medicare supplement, medicare part D, and other ancillary senior health insurance related policies, including prescription drugs, dental, vision, and hearing plans; term life policies; and non-commercial auto and home property, and casualty policies. The company was incorporated in 1999 and is headquartered in Overland Park, Kansas.
How the Company Makes MoneySelectQuote generates revenue primarily through commissions earned on the sale of insurance policies. The company partners with numerous insurance carriers, receiving a commission for each policy sold through its platform. This commission-based model allows SelectQuote to monetize its extensive customer base effectively. Additionally, the company may earn referral fees for directing customers to specific insurance providers. SelectQuote's focus on providing a transparent and user-friendly experience attracts a wide audience, contributing to its revenue growth. The company also invests in marketing and technology to enhance its services and expand its reach within the insurance marketplace.

SelectQuote Earnings Call Summary

Earnings Call Date:Nov 06, 2025
(Q1-2026)
|
% Change Since: |
Next Earnings Date:Feb 09, 2026
Earnings Call Sentiment Neutral
SelectQuote experienced both positive and negative trends during the fiscal first quarter. The company achieved significant revenue growth in its consolidated and Life Insurance business, alongside operational achievements with the new Kansas facility. However, it faced challenges with declines in Senior segment revenues due to policy changes and a significant EBITDA impact in Healthcare Services caused by reimbursement rate adjustments. These challenges have led to unmet fiscal targets, impacting overall sentiment.
Q1-2026 Updates
Positive Updates
Consolidated Revenue Growth
SelectQuote generated consolidated revenue of $329 million, representing a 13% growth over the same period a year ago, driven by strong growth in Healthcare Services.
Life Insurance Business Growth
Revenues expanded nearly 20% in the Life Insurance segment, driven by balanced growth in term life and final expense policies.
New Kansas Facility
The new Kansas facility is ramping as planned, delivering efficiency gains in line with expectations.
SelectRx Clinical Value
SelectRx improves medication adherence and health outcomes, reducing hospital days by around 20% for members, which benefits the healthcare system.
Negative Updates
Senior Revenue Decline
Senior revenues were $59 million compared to $93 million a year ago, driven by a 32% fewer policies due to changes in beneficiary eligibility requirements.
Healthcare Services EBITDA Impact
First quarter Healthcare Services EBITDA was impacted by a change in drug reimbursement rates with a SelectRx PBM partner, affecting the first half of the fiscal year by approximately $20 million.
Consolidated EBITDA Loss
Quarterly EBITDA was negative $32 million, below the guided loss range of $25 million to $30 million due to SelectRx margin dynamics.
Unmet Fiscal Targets
SelectQuote no longer anticipates reaching its $50 million EBITDA target for fiscal '26, aiming instead for an annualized run rate of $40 million to $50 million by year-end.
Company Guidance
During the SelectQuote fiscal first quarter earnings call, several key metrics and guidance were highlighted. The company reported consolidated revenue of $329 million, marking a 13% year-over-year increase, primarily driven by growth in Healthcare Services. However, the Senior segment experienced a 37% decline in revenue to $59 million due to changes in beneficiary eligibility requirements during the special election period, leading to a negative EBITDA of $21 million. Despite this, the company is optimistic about the upcoming Annual Enrollment Period (AEP) and expects to exit fiscal 2026 with an annualized EBITDA run rate between $40 million and $50 million. Additionally, SelectQuote faced a $20 million headwind in Healthcare Services due to a change in drug reimbursement rates from a pharmacy benefit manager (PBM) partner, impacting first and second quarter EBITDA margins. The company remains confident in reaching a longer-term agreement with the PBM, expecting normalized reimbursement rates by January 1, 2026. Overall, SelectQuote maintained its fiscal 2026 financial outlook, projecting revenues of $1.65 billion to $1.75 billion and adjusted EBITDA between $120 million and $150 million, with expectations to be operating cash flow positive for the year.

SelectQuote Financial Statement Overview

Summary
SelectQuote shows signs of recovery with improved revenue growth and gross profit margins. However, profitability remains a concern with low net profit margins and negative operating cash flow. The reduction in leverage is a positive sign, but the company needs to address cash flow challenges to ensure long-term financial health.
Income Statement
65
Positive
SelectQuote has shown a positive revenue growth trend with a TTM revenue growth rate of 2.39%. The gross profit margin has improved significantly from 45.24% in 2024 to 61.30% in TTM, indicating better cost management. However, the net profit margin remains low at 3.12% in TTM, suggesting limited profitability. The EBIT and EBITDA margins have improved but are still modest, reflecting operational challenges.
Balance Sheet
58
Neutral
The company's debt-to-equity ratio has improved to 0.17 in TTM from a high of 2.25 in 2024, indicating reduced leverage and better financial stability. However, the return on equity is relatively low at 11.01% in TTM, suggesting limited returns for shareholders. The equity ratio is not provided, which limits a full assessment of asset financing.
Cash Flow
50
Neutral
SelectQuote's cash flow situation is challenging, with negative operating cash flow in TTM. The free cash flow growth rate is positive at 40.62% in TTM, but the operating cash flow to net income ratio is negative, indicating cash flow issues. The free cash flow to net income ratio is strong at 1.19, suggesting efficient cash generation relative to net income.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.56B1.53B1.32B1.00B764.04M929.98M
Gross Profit723.36M591.13M597.97M475.36M308.35M659.27M
EBITDA133.19M148.36M89.48M39.34M-321.49M203.48M
Net Income61.67M47.58M-34.13M-58.54M-297.50M124.86M
Balance Sheet
Total Assets1.21B1.25B1.19B1.22B1.29B1.43B
Cash, Cash Equivalents and Short-Term Investments14.46M32.40M42.69M83.16M141.00M286.45M
Total Debt98.03M415.91M713.92M731.58M744.80M505.30M
Total Liabilities660.05M673.84M877.11M872.28M898.95M758.98M
Stockholders Equity305.07M575.52M316.80M346.97M391.11M674.89M
Cash Flow
Free Cash Flow-19.49M-13.86M11.85M-28.50M-372.96M-138.43M
Operating Cash Flow-16.68M-11.67M15.24M-19.38M-338.31M-115.44M
Investing Cash Flow-12.72M-11.31M-14.85M-9.13M-42.58M-64.02M
Financing Cash Flow34.66M17.36M-40.86M-29.34M235.43M97.04M

SelectQuote Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.73
Price Trends
50DMA
2.02
Negative
100DMA
2.09
Negative
200DMA
2.75
Negative
Market Momentum
MACD
-0.03
Positive
RSI
36.25
Neutral
STOCH
28.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLQT, the sentiment is Negative. The current price of 1.73 is below the 20-day moving average (MA) of 1.98, below the 50-day MA of 2.02, and below the 200-day MA of 2.75, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 36.25 is Neutral, neither overbought nor oversold. The STOCH value of 28.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLQT.

SelectQuote Risk Analysis

SelectQuote disclosed 54 risk factors in its most recent earnings report. SelectQuote reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

SelectQuote Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
57
Neutral
$35.11M13.164.56%19.30%-17.56%
49
Neutral
$295.49M15.11%13.16%
45
Neutral
$117.95M109.975.88%16.79%
44
Neutral
$4.20M-223.86%1.07%96.67%
42
Neutral
$56.44M-0.93-13.38%17.46%60.17%
41
Neutral
$26.98M-1.75-11.18%624.24%85.46%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SLQT
SelectQuote
1.73
-0.72
-29.39%
EHTH
Ehealth
4.08
-1.19
-22.58%
RELI
Reliance Global Group
0.84
-1.02
-54.84%
HUIZ
Huize Holding
3.28
-0.67
-16.96%
TIRX
Tian Ruixiang Holdings
0.85
-8.15
-90.56%
GOCO
GoHealth
3.39
-8.15
-70.62%

SelectQuote Corporate Events

SelectQuote Inc. Reports Q1 FY2026 Financial Results
Nov 7, 2025

SelectQuote Inc., a company specializing in offering unbiased insurance comparisons, operates primarily in the insurance and healthcare services sectors. The company provides a range of services including Medicare Advantage plans, prescription drug delivery, and life insurance.

SelectQuote Earnings Call: Mixed Sentiment and Strategic Outlook
Nov 7, 2025

SelectQuote’s recent earnings call revealed a mixed sentiment, reflecting both achievements and challenges faced by the company. On the positive side, SelectQuote reported significant revenue growth in its consolidated and Life Insurance business, alongside operational successes with the new Kansas facility. However, the company encountered difficulties with declining revenues in the Senior segment due to policy changes and a substantial EBITDA impact in Healthcare Services caused by reimbursement rate adjustments. These hurdles have led to unmet fiscal targets, impacting the overall sentiment of the earnings call.

SelectQuote Inc’s Earnings Call Highlights Growth Amid Challenges
Sep 1, 2025

During SelectQuote Inc’s recent earnings call, the sentiment was notably positive, driven by strong revenue growth and impressive agent productivity. However, the company acknowledged challenges in the Medicare Advantage market and anticipated lower EBITDA margins in fiscal 2026. The integration of technology and AI was highlighted as a promising avenue for future efficiency gains.

SelectQuote Inc. Reports Strong Q4 2025 Results
Aug 22, 2025

SelectQuote Inc., a company specializing in providing insurance comparisons and healthcare services, operates in the insurance and healthcare sectors, offering a unique blend of insurance brokerage and healthcare solutions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 07, 2025